The Synaptic Therapy Alzheimer's Research Trial (START) represents a groundbreaking Phase 2 clinical trial evaluating CT1812, a novel sigma-2 receptor modulator developed by Cognition Therapeutics. This randomized, double-blind, placebo-controlled, parallel-group study aims to evaluate the safety and efficacy of CT1812 in individuals with early Alzheimer's disease over an 18-month treatment period.
CT1812 represents a fundamentally different approach to Alzheimer's disease therapy. Rather than targeting amyloid-beta plaques directly—the strategy that has dominated AD drug development for decades—CT1812 acts on the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. This mechanism addresses what many researchers now consider the most pathogenic form of amyloid-beta: the soluble oligomeric species that disrupt synaptic function and lead to cognitive decline[1][2].
Alzheimer's disease affects approximately 55 million people worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments that preserve synaptic integrity, underscores the critical importance of clinical trials like START in advancing our therapeutic options[3].
| Parameter | Value |
|---|---|
| NCT Number | NCT05531656 |
| Phase | Phase 2 |
| Status | Active, Not Recruiting |
| Sponsor | Cognition Therapeutics |
| Enrollment | 540 participants |
| Enrollment Type | Estimated |
| Study Type | Interventional |
| Randomization | 2:1 (CT1812:Placebo) |
| Start Date | June 28, 2023 |
| Completion Date | April 1, 2027 |
| Last Updated | September 22, 2025 |
The sigma-2 receptor is a distinct membrane protein receptor expressed predominantly in the central nervous system, particularly in regions critical for learning and memory such as the hippocampus and prefrontal cortex. Unlike sigma-1 receptor which has been studied extensively for its role in cellular stress responses, the sigma-2 receptor has emerged as a key regulator of synaptic function and neuronal survival[1:1].
CT1812 is a highly selective sigma-2 receptor modulator that:
Blocks Amyloid-Beta Oligomer Binding: Sigma-2 receptors serve as binding sites for toxic amyloid-beta oligomers on neuronal membranes. CT1812 competitively inhibits this binding, preventing oligomers from entering neurons and disrupting synaptic function.
Preserves Synaptic Integrity: By blocking oligomer binding, CT1812 protects the postsynaptic density and prevents the loss of dendritic spines that correlates with cognitive decline in AD[4].
Restores Synaptic Function: Preclinical studies demonstrate that CT1812 can reverse synaptic deficits induced by amyloid-beta oligomers, including improvements in long-term potentiation (LTP) and synaptic plasticity markers.
Reduces Neuroinflammation: Sigma-2 receptor modulation has been shown to reduce microglial activation and neuroinflammatory responses associated with AD pathology.
The shift in focus from amyloid-beta plaques to soluble oligomers represents a major paradigm shift in AD research. While plaques have long been the pathological hallmark of AD, increasing evidence indicates that:
CT1812's mechanism specifically targets these toxic oligomeric species, potentially offering disease-modifying effects by protecting the most vulnerable synaptic connections[2:1][5].
This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial with a 2:1 randomization ratio (two participants receive CT1812 for every one receiving placebo). This design maximizes exposure to the investigational treatment while maintaining statistical power[6].
| Arm | Treatment | Dose | Duration |
|---|---|---|---|
| A | CT1812 | 300 mg daily | 18 months |
| B | CT1812 | 100 mg daily | 18 months |
| C | Placebo | N/A | 18 months |
Enriched Population: All participants must have confirmed amyloid pathology, ensuring the study population has the biological target for the intervention.
Early Disease Stage: By enrolling participants with early AD (MCI or mild dementia), the trial captures individuals most likely to benefit from disease-modifying interventions before extensive synaptic loss occurs.
Long Duration: The 18-month treatment period allows assessment of disease modification rather than just symptomatic effects.
Biomarker Substudy: Participants have the option to enroll in a CSF biomarker substudy to assess changes in tau, phosphorylated tau (p-tau), and amyloid-beta levels.
Cognitive Measures:
Functional Measures:
Biomarker Endpoints:
Brain Imaging:
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease that target synaptic protection rather than amyloid clearance. The outcomes of this study may[7]:
Validate sigma-2 as a therapeutic target: If successful, CT1812 would provide first-in-class validation of sigma-2 receptor modulation as a viable AD treatment strategy.
Shift toward oligomer-targeted therapies: The trial validates the therapeutic relevance of targeting amyloid-beta oligomers rather than plaques.
Inform precision medicine approaches: Biomarker data may help identify which patients respond best to sigma-2 modulation.
Preserve cognitive function: By protecting synapses from oligomer toxicity, CT1812 may slow or prevent the cognitive decline that defines AD.
Disease modification: The mechanism addresses the underlying pathological process rather than symptoms, potentially offering durable benefits.
Combination potential: Sigma-2 modulators could potentially be combined with amyloid-clearing antibodies (lecanemab, donanemab) for synergistic effects.
Positive results from START could support advancement to Phase 3 trials and potentially provide a new treatment modality for early AD patients who currently have limited therapeutic options beyond amyloid-targeting antibodies.
The trial is being conducted at multiple centers across the United States, including:
| State | City |
|---|---|
| Alabama | Birmingham |
| Arizona | Phoenix, Sun City |
| California | Irvine, Palo Alto |
| Florida | Clearwater, Orlando, Tampa |
| Georgia | Atlanta |
| Illinois | Chicago |
| Massachusetts | Boston |
| New York | Buffalo, New York |
| Ohio | Cleveland |
| Pennsylvania | Philadelphia |
| Texas | Dallas, Houston |
CT1812 has undergone extensive preclinical evaluation demonstrating[5:1]:
Phase 1 clinical trials established:
As of the latest update, the START trial is actively following participants through the 18-month treatment period. Results are expected in 2027. If positive, the trial will advance to Phase 3 development with the goal of bringing this novel synaptic protection mechanism to patients with early AD.
This trial represents an important paradigm shift in AD drug development—from targeting amyloid plaque removal to protecting synaptic function from the most toxic form of amyloid-beta. Regardless of outcome, the START trial will provide valuable insights into the sigma-2 receptor as a therapeutic target and the role of amyloid-beta oligomers in AD pathogenesis.
Sigma-2 receptor modulators as novel therapeutic agents for Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics. 2023. ↩︎ ↩︎
Targeting amyloid-beta oligomers with sigma-2 receptor modulators. Cell Reports. 2021. ↩︎ ↩︎
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23). 2023. ↩︎
Synaptic dysfunction in Alzheimer's disease: mechanisms and therapeutic targets. Nature Reviews Neuroscience. 2022. ↩︎
CT1812: A first-in-class sigma-2 receptor modulator for Alzheimer's disease. Alzheimer's & Dementia. 2021. ↩︎ ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎